Presentation is loading. Please wait.

Presentation is loading. Please wait.

A, cytotoxicity induced on HER2 3+ USC (ARK-2), HER2 0/1+ USC (ARK-4), and ARK-2/ARK-4 cocultures with 1 μg/mL of SYD985, T-DM1, and ADC isotype control.

Published byShannon Parks Modified over 4 years ago

Similar presentations

Presentation on theme: "A, cytotoxicity induced on HER2 3+ USC (ARK-2), HER2 0/1+ USC (ARK-4), and ARK-2/ARK-4 cocultures with 1 μg/mL of SYD985, T-DM1, and ADC isotype control."— Presentation transcript:

1 A, cytotoxicity induced on HER2 3+ USC (ARK-2), HER2 0/1+ USC (ARK-4), and ARK-2/ARK-4 cocultures with 1 μg/mL of SYD985, T-DM1, and ADC isotype control. A, cytotoxicity induced on HER2 3+ USC (ARK-2), HER2 0/1+ USC (ARK-4), and ARK-2/ARK-4 cocultures with 1 μg/mL of SYD985, T-DM1, and ADC isotype control. A significant increase in the amount of killing of HER2 0/1+ USC cells was detected when compared with control (P = 0.001) after treatment with SYD985. B, cytotoxicity induced on HER2 3+ USC (ARK-2), HER2 0/1+ USC (ARK-4), and ARK-2/ARK-4 cocultures with 1 μg/mL of SYD995 (T-DM1). No significant increase in the amount of killing of HER2 0/1+ USC cells was detected when compared with control (P = 0.29) after treatment with T-DM1. C, cytotoxicity induced on HER2 3+ USC (ARK-2), HER2 0/1+ USC (ARK-4), and ARK-2/ARK-4 cocultures with 1 μg/mL of SYD989 (isotype control ADC). No significant increase in the amount of killing of HER2 0/1+ USC cells was detected when compared with control (P = 0.51) after treatment with isotype control ADC. Jonathan Black et al. Mol Cancer Ther 2016;15: ©2016 by American Association for Cancer Research

Download ppt "A, cytotoxicity induced on HER2 3+ USC (ARK-2), HER2 0/1+ USC (ARK-4), and ARK-2/ARK-4 cocultures with 1 μg/mL of SYD985, T-DM1, and ADC isotype control."

Similar presentations

Selinexor combines with immune checkpoint blockade to slow B16F10 melanoma tumor growth. Selinexor combines with immune checkpoint blockade to slow B16F10.

Selinexor combines with immune checkpoint blockade to slow B16F10 melanoma tumor growth. Selinexor combines with immune checkpoint blockade to slow B16F10.
Targeting the PARP DNA repair pathway enhanced cytotoxicity induced by chemotherapy. Targeting the PARP DNA repair pathway enhanced cytotoxicity induced.

Targeting the PARP DNA repair pathway enhanced cytotoxicity induced by chemotherapy. Targeting the PARP DNA repair pathway enhanced cytotoxicity induced.
Strategies for differential inhibition of mTORC1 and mTORC2 with rapamycin. Strategies for differential inhibition of mTORC1 and mTORC2 with rapamycin.

Strategies for differential inhibition of mTORC1 and mTORC2 with rapamycin. Strategies for differential inhibition of mTORC1 and mTORC2 with rapamycin.
Antitumor activity of BAY in patient-derived tumor models.

Antitumor activity of BAY in patient-derived tumor models.
Effects of SC144 on in vivo ovarian tumor.

Effects of SC144 on in vivo ovarian tumor.
NM-3 induces p21 levels and down-regulation of Cdk2 activity.

NM-3 induces p21 levels and down-regulation of Cdk2 activity.
Genetic and pharmacologic inactivation of KSR1 radiosensitizes A431 cells in vitro to the lethal effect of ionizing radiation. Genetic and pharmacologic.

Genetic and pharmacologic inactivation of KSR1 radiosensitizes A431 cells in vitro to the lethal effect of ionizing radiation. Genetic and pharmacologic.
Effect of CD4+ Th1 cytokines and HER2-targeted antibodies on MHC class I restoration and HER2369–377-CD8+ T-cell targeting of HER2-expressing cancer cells.

Effect of CD4+ Th1 cytokines and HER2-targeted antibodies on MHC class I restoration and HER2369–377-CD8+ T-cell targeting of HER2-expressing cancer cells.
A, IC50 dose–response curves of SYD985, T-DM1, and ADC isotype control in all USC cell lines tested in vitro (i.e., HER2 3+ cell lines, P =

A, IC50 dose–response curves of SYD985, T-DM1, and ADC isotype control in all USC cell lines tested in vitro (i.e., HER2 3+ cell lines, P =
Apoptosis induced by ssHHT in HL60 and its derivative, the HL60/MRP, cells. Apoptosis induced by ssHHT in HL60 and its derivative, the HL60/MRP, cells.

Apoptosis induced by ssHHT in HL60 and its derivative, the HL60/MRP, cells. Apoptosis induced by ssHHT in HL60 and its derivative, the HL60/MRP, cells.
Assessing the effect of TNF-α and TRAIL on A2-PPI15–24 CD8 T-cell cytotoxicity. Assessing the effect of TNF-α and TRAIL on A2-PPI15–24 CD8 T-cell cytotoxicity.

Assessing the effect of TNF-α and TRAIL on A2-PPI15–24 CD8 T-cell cytotoxicity. Assessing the effect of TNF-α and TRAIL on A2-PPI15–24 CD8 T-cell cytotoxicity.
GA blocks HIF activity and reduces HIF target expression.

GA blocks HIF activity and reduces HIF target expression.
Immunohistochemical detection of 8-OHdG by use of the 1F7 monoclonal antibody in oligomer-treated PC3 prostate cancer cells. a, control untreated peripheral.

Immunohistochemical detection of 8-OHdG by use of the 1F7 monoclonal antibody in oligomer-treated PC3 prostate cancer cells. a, control untreated peripheral.
A, rate of proliferation of PC3 prostate cancer cells is greatly reduced by treatment with oligomers containing CpG motifs, as assessed by (a) soft agar.

A, rate of proliferation of PC3 prostate cancer cells is greatly reduced by treatment with oligomers containing CpG motifs, as assessed by (a) soft agar.
Cytotoxic activity of HER2-lytic hybrid peptide.

Cytotoxic activity of HER2-lytic hybrid peptide.
Diagnostic plots of the TGI PKPD model fitted to the A677 TGI data.

Diagnostic plots of the TGI PKPD model fitted to the A677 TGI data.
Representative Western blot analyses of S-phase and other proteins from PC3 cell lysates obtained 3 days after oligomer (400 nm)/Lipofectin (15 μg/ml)

Representative Western blot analyses of S-phase and other proteins from PC3 cell lysates obtained 3 days after oligomer (400 nm)/Lipofectin (15 μg/ml)
A, ATP production by PC3 prostate cancer cells after treatment with oligonucleotide/Lipofectin complexes. a, ATP production by PC3 prostate cancer cells.

A, ATP production by PC3 prostate cancer cells after treatment with oligonucleotide/Lipofectin complexes. a, ATP production by PC3 prostate cancer cells.
Stimulatory effect induced by docetaxel, gefitinib, and cyclopamine on MMP (A) and (B) cytosolic cytochrome c level. Stimulatory effect induced by docetaxel,

Stimulatory effect induced by docetaxel, gefitinib, and cyclopamine on MMP (A) and (B) cytosolic cytochrome c level. Stimulatory effect induced by docetaxel,
Antitumor activity of HER2-lytic hybrid peptide in tumor xenograft model in vivo. Antitumor activity of HER2-lytic hybrid peptide in tumor xenograft model.

Antitumor activity of HER2-lytic hybrid peptide in tumor xenograft model in vivo. Antitumor activity of HER2-lytic hybrid peptide in tumor xenograft model.

Similar presentations

Ads by Google